# US 2018/0022826 A1 · ADOPTIVE T-CELL THERAPY USING EMPD-SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR TREATING IgE-MEDIATED ALLERGIC DISEASES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022826 A1
- Document ID: US20180022826A1
- Status: Published application
- Kind: A1
- Application number: 15/651,264
- Filed: 2017-07-17
- Published: 2018-01-25
- Earliest claimed: 2016-07-25
- Assignees: The Nemours Foundation
- Applicants: The Nemours Foundation
- Inventors: ZHENGYU MA
- Web page: https://patentgrep.com/patent/US20180022826A1

## CPC

- C07K 16/4291: {against IgE}
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G02F 1/09: based on magneto-optical elements, e.g. exhibiting Faraday effect
- A61K 2039/505: {comprising antibodies}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2510/00: Genetically modified cells
- C12N 2800/00: Nucleic acids vectors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G02F: OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

## Claims

### Claim 1

An EMPD-specific chimeric antigen receptor comprising an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon binding of EMPD to the extracellular ligand binding domain.

### Claim 2 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the extracellular ligand binding domain comprises a single chain Fv fragment comprising a light chain variable region comprising the complementarity determining regions SEQ ID NO:32, Trp-Ala-Ser and SEQ ID NO:33, and a heavy chain variable region comprising the complementarity determining regions SEQ ID NO: 34, SEQ ID NO:35 and SEQ ID NO:36.

### Claim 3 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the extracellular ligand binding domain comprises a single chain Fv fragment comprising a light chain variable region comprising the complementarity determining regions SEQ ID NO:37, Trp-Ala-Ser and SEQ ID NO:38, and a heavy chain variable region comprising the complementarity determining regions SEQ ID NO:39, SEQ ID NO:40 and SEQ ID NO:41.

### Claim 4 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the extracellular ligand binding domain comprises a single chain Fv fragment comprising a light chain variable region comprising the complementarity determining regions SEQ ID NO:42, Leu-Val-Ser and SEQ ID NO:43, and a heavy chain variable region comprising the complementarity determining regions SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.

### Claim 5 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the extracellular ligand binding domain comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 275 of SEQ ID NO:9. said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker ; or
(iii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 6 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the extracellular ligand binding domain comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said variable light chain and variable heavy chain being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said variable light chain and variable heavy chain being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said variable light chain and variable heavy chain being connected by a sequence of amino acids forming a flexible linker.

### Claim 7 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 which binds to the same EMPD epitope as one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31.

### Claim 8 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the intracellular domain comprises an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM).

### Claim 9 (depends on 8)

The EMPD-specific chimeric antigen receptor of claim 8 wherein the intracellular signaling domain comprises a CD3t signaling domain.

### Claim 10 (depends on 9)

The EMPD-specific chimeric antigen receptor of claim 9 wherein the CD3 signaling domain comprises the amino acid sequence SEQ ID NO: 12.

### Claim 11 (depends on 8)

The EMPD-specific chimeric antigen receptor of claim 8 wherein the intracellular domain comprises a costimulatory signaling domain.

### Claim 12 (depends on 11)

The EMPD-specific chimeric antigen receptor of claim 11 wherein the costimulatory signaling domain comprises at least the intracellular domain of at least one of 4-1BB, CD27, CD28, CD134 or ICOS.

### Claim 13 (depends on 12)

The EMPD-specific chimeric antigen receptor of claim 12 wherein the costimulatory signaling domain comprises at least the intracellular domain of CD28 or 4-1BB, or at least the intracellular domains of both CD28 and 4-1BB.

### Claim 14 (depends on 12)

The EMPD-specific chimeric antigen receptor of claim 12 wherein the costimulatory signaling domain comprises the amino acid sequence SEQ ID NO:48.

### Claim 15 (depends on 1)

The EMPD-specific chimeric antigen receptor of claim 1 wherein the transmembrane domain comprises the amino acid sequence SEQ ID NO:22

### Claim 16 (depends on 8)

The EMPD-specific chimeric antigen receptor of claim 8 comprising an amino acid sequence selected from the group of amino sequences consisting of the following:
(a) SEQ ID NO:7;
(b) the sequence of amino acids from amino acid 23 to amino acid 559 of SEQ ID NO:7;
(c) SEQ ID NO:9;
(d) the sequence of amino acids from amino acid 23 to amino acid 554 of SEQ ID NO:9;
(e) SEQ ID NO:31; and
(f) the sequence of amino acids from amino acid 23 to amino acid 552 of SEQ ID NO:31.

### Claim 17

An isolated nucleic acid sequence encoding an EMPD-specific chimeric antigen receptor wherein the an EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon binding of EMPD to the extracellular ligand binding domain.

### Claim 18 (depends on 17)

The isolated nucleic acid sequence according to claim 17, wherein the encoded extracellular ligand binding domain comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 19 (depends on 17)

The isolated nucleic acid sequence according to claim 17, wherein the encoded extracellular ligand binding domain comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 20 (depends on 17)

The isolated nucleic acid sequence according to claim 17, wherein the encoded EMPD-specific chimeric antigen receptor binds to the same EMPD epitope as one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 21 (depends on 17)

The isolated nucleic acid sequence according to claim 17, wherein the encoded intracellular domain comprises an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM).

### Claim 22 (depends on 21)

The isolated nucleic acid sequence according to claim 21, wherein the encoded intracellular signaling domain comprises a CD3 signaling domain.

### Claim 23 (depends on 22)

The isolated nucleic acid sequence according to claim 22, wherein the encoded CD3t signaling domain comprises the amino acid sequence SEQ ID NO: 12.

### Claim 24 (depends on 21)

The isolated nucleic acid sequence according to claim 21, wherein the encoded intracellular domain comprises a costimulatory signaling domain.

### Claim 25 (depends on 24)

The isolated nucleic acid sequence according to claim 24, wherein the encoded costimulatory signaling domain comprises at least the intracellular domain of at least one of 4-1BB, CD27, CD28, CD134 or ICOS.

### Claim 26 (depends on 25)

The isolated nucleic acid sequence according to claim 25, wherein the encoded costimulatory signaling domain comprises at least the intracellular domain of CD28 or 4-1BB, or at least the intracellular domains of both CD28 and 4-1BB.

### Claim 27 (depends on 25)

The isolated nucleic acid sequence according to claim 25, wherein the encoded costimulatory signaling domain comprises the amino acid sequence SEQ ID NO:48.

### Claim 28 (depends on 21)

The isolated nucleic acid sequence according to claim 21, wherein the nucleic acid sequence encodes an EMPD-specific chimeric antigen receptor having an amino acid sequence selected from the group of amino sequences consisting of the following:
(a) SEQ ID NO:7;
(b) the sequence of amino acids from amino acid 23 to amino acid 559 of SEQ ID NO:7;
(c) SEQ ID NO:9;
(d) the sequence of amino acids from amino acid 23 to amino acid 554 of SEQ ID NO:9;
(e) SEQ ID NO:31; and
(f) the sequence of amino acids from amino acid 23 to amino acid 552 of SEQ ID NO:31.

### Claim 29 (depends on 28)

The isolated nucleic acid sequence according to claim 28, comprising a nucleic acid sequence selected from the group consisting of::
(a) SEQ ID NO:6;
(b) the sequence of nucleotides from nucleotide 67 to nucleotide 1677 of SEQ ID NO:6;
(c) SEQ ID NO:8;
(d) the sequence of nucleotides from nucleotide 67 to nucleotide 1662 of SEQ ID NO:8;
(e) SEQ ID NO:30; and
(f) the sequence of nucleotides from nucleotide 67 to nucleotide 1656 of SEQ ID NO: 30.

### Claim 30

A T cell comprising a nucleic acid sequence encoding an EMPD-specific chimeric antigen receptor, wherein the EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon binding of EMPD to the extracellular ligand binding domain.

### Claim 31

A T cell expressing an EMPD-specific chimeric antigen receptor, wherein the EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon binding of EMPD to the extracellular ligand binding domain.

### Claim 32 (depends on 31)

The T cell according to claim 31, wherein the extracellular ligand binding domain of the EMPD-specific chimeric antigen receptor comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising complementarity determining regions SEQ ID NO:32, Trp-Ala-Ser and SEQ ID NO:33, and a heavy chain variable region comprising the complementarity determining regions SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising complementarity determining regions SEQ ID NO:37, Trp-Ala-Ser and SEQ ID NO:38, and a heavy chain variable region comprising the complementarity determining regions SEQ ID NO:39, SEQ ID NO:40 and SEQ ID NO:41, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising complementarity determining regions SEQ ID NO:42, Leu-Val-Ser and SEQ ID NO:43, and a heavy chain variable region comprising the complementarity determining regions SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 33 (depends on 31)

The T cell according to claim 31, wherein the extracellular ligand binding domain of the EMPD-specific chimeric antigen receptor comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 34 (depends on 31)

The T cell according to claim 31, wherein the extracellular ligand binding domain of the EMPD-specific chimeric antigen receptor comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 35 (depends on 31)

The T cell according to claim 31, wherein the extracellular ligand binding domain of the EMPD-specific chimeric antigen receptor comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 36 (depends on 31)

The T cell according to claim 31, wherein the intracellular domain comprises an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM).

### Claim 37 (depends on 36)

The T cell according to claim 36, wherein the intracellular signaling domain comprises a CD3ζ signaling domain.

### Claim 38 (depends on 37)

The T cell according to claim 37, wherein the CD3 signaling domain comprises the amino acid sequence SEQ ID NO: 12.

### Claim 39 (depends on 36)

The T cell according to claim 36, wherein the EMPD-specific chimeric antigen receptor further comprises a costimulatory signaling domain.

### Claim 40 (depends on 39)

The T cell according to claim 39 wherein the costimulatory signaling domain comprises at least the intracellular domain of at least one of 4-1BB, CD27, CD28, CD134 or ICOS.

### Claim 41 (depends on 40)

The T cell according to claim 40 wherein the costimulatory signaling domain comprises at least the intracellular domain of CD28 or 4-1BB, or at least the intracellular domains of both CD28 and 4-1BB.

### Claim 42 (depends on 40)

The T cell according to claim 40 wherein the costimulatory signaling domain comprises the amino acid sequence SEQ ID NO: 48.

### Claim 43 (depends on 31)

The T cell according to claim 31, wherein the transmembrane domain has the amino acid sequence SEQ ID NO: 12.

### Claim 44 (depends on 36)

The T cell according to claim 36, wherein the EMPD-specific chimeric antigen receptor comprises an amino acid sequence selected from the group of amino sequences consisting of the following:
(a) SEQ ID NO:7;
(b) the sequence of amino acids from amino acid 23 to amino acid 559 of SEQ ID NO:7;
(c) SEQ ID NO:9;
(d) the sequence of amino acids from amino acid 23 to amino acid 554 of SEQ ID NO:9;
(e) SEQ ID NO:31; and
(f) the sequence of amino acids from amino acid 23 to amino acid 552 of SEQ ID NO:31.

### Claim 45

A vector comprising a nucleic acid sequence encoding an EMPD-specific chimeric antigen receptor wherein the an EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon binding of EMPD to the extracellular ligand binding domain.

### Claim 46 (depends on 45)

The vector according to claim 45, wherein the encoded extracellular ligand binding domain comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region having at least 95% sequence identity with the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region having at least 95% sequence identity with the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 47 (depends on 45)

The vector according to claim 45, wherein the encoded extracellular ligand binding domain comprises one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 48 (depends on 45)

The vector according to claim 45, wherein the encoded EMPD-specific chimeric antigen receptor binds to the same EMPD epitope as one of the following single chain Fv fragments:
(i) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:7 and a heavy chain variable region comprising the sequence of amino acids 152 to 275 of SEQ ID NO:7, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker;
(ii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 136 of SEQ ID NO:9 and a heavy chain variable region comprising the sequence of amino acids 152 to 270 of SEQ ID NO:9, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker; or
(iii) a single chain Fv fragment comprising a light chain variable region comprising the sequence of amino acids 23 to 135 of SEQ ID NO:31 and a heavy chain variable region comprising the sequence of amino acids 151 to 268 of SEQ ID NO:31, said light chain variable region and heavy chain variable region being connected by a sequence of amino acids forming a flexible linker.

### Claim 49 (depends on 45)

The vector according to claim 45, wherein the encoded intracellular domain comprises an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM).

### Claim 50 (depends on 46)

The vector according to claim 46, wherein the encoded intracellular signaling domain comprises a CD3t signaling domain.

### Claim 51 (depends on 49)

The vector according to claim 49, wherein the encoded intracellular domain comprises a costimulatory signaling domain.

### Claim 52 (depends on 51)

The vector according to claim 51, wherein the encoded costimulatory signaling domain comprises at least the intracellular domain of at least one of 4-1BB, CD27, CD28, CD134 or ICOS.

### Claim 53 (depends on 52)

The vector according to claim 52, wherein the encoded costimulatory signaling domain comprises at least the intracellular domain of CD28 or 4-1BB, or at least the intracellular domains of both CD28 and 4-1BB.

### Claim 54 (depends on 52)

The vector according to claim 52, wherein the encoded costimulatory signaling domain comprises the amino acid sequence SEQ ID NO: 48.

### Claim 55 (depends on 49)

The vector according to claim 49, wherein the nucleic acid sequence encodes an EMPD-specific chimeric antigen receptor comprising an amino acid sequence selected from the group of amino sequences consisting of the following:
(a) SEQ ID NO: 7;
(b) the sequence of amino acids from amino acid 23 to amino acid 559 of SEQ ID NO:7;
(c) SEQ ID NO: 9;
(d) the sequence of amino acids from amino acid 23 to amino acid 554 of SEQ ID NO:9;
(e) SEQ ID NO:31; and
(f) the sequence of amino acids from amino acid 23 to amino acid 552 of SEQ ID NO:31.

### Claim 56 (depends on 55)

The vector according to claim 55, comprising a nucleic acid sequence selected from the group consisting of:
(a) SEQ ID NO:6;
(b) the sequence of nucleotides from nucleotide 67 to nucleotide 1677 of SEQ ID NO:6;
(c) SEQ ID NO:8;
(d) the sequence of nucleotides from nucleotide 67 to nucleotide 1662 of SEQ ID NO:8;
(e) SEQ ID NO:30; and
(f) the sequence of nucleotides from nucleotide 67 to nucleotide 1656 of SEQ ID NO: 30.

### Claim 57 (depends on 31)

A method for stimulating a T cell-mediated immune response to cells expressing mIgE in a subject, the method comprising administering to the subject an effective amount of T cells according to claim 31.

### Claim 58 (depends on 57)

The method according to claim 57 wherein the T cells comprise autologous T cells that are removed from the subject and engineered ex vivo to express said CAR and administered to the subject.

### Claim 59 (depends on 31)

A method for treating an IgE-mediated allergic disease in a subject in need of such treatment, or for preventing an IgE-mediated allergic disease in a subject at risk of such disease, comprising administering to the subject an effective amount of T cells according to claim 31.

### Claim 60 (depends on 59)

The method according to claim 59 wherein the T cells comprise autologous T cells that are removed from the subject and engineered ex vivo to express said CAR and administered to the subject.

### Claim 61 (depends on 59)

The method according to claim 59 wherein the disease is selected from the group consisting of allergic asthma, food allergy, atopic dermatitis, allergic rhinitis, allergic rhinoconjunctivitis, chronic urticaria and systematic anaphylaxis.
